Innate Immunocytes Can Cure Malignancies: Indo-Japanese Oncologists
Instead of chemotherapy regimens, a team of Indian and Japanese oncologists advocated the use of patient’s own immunocytes against malignancies. They explained the cancer can be better managed with innate immunocytes than conventional chemotherapeutic drugs. The scientists explained the clinical significance of immunocytes in the seventh international conference of Niche-In Center for Regenerative Medicine held in Chennai.
Citing epidemiological data, the Japanese researcher Prof. Iwasaki and Dr. Terunuma from Yamanashi said more than 30% of Japanese people are being affected by cancer and the patients are being treated by Autologous Immune Enhancement Therapy (AIET). The Japanese are using innate immunocytes such as autologous cell therapies by using natural killer cells, T-lymphocytes and TNF-α to treat malignancies and the results are promising. The autologous cells are harvested from peripheral blood, cultured in-vitro and infused into the patient’s blood stream.
According to the Japanese scientists, AIET can be employed with or without combination of anti-cancer drugs at any stages of disease without adverse events. The treatment outcome can significantly increase the survival rate by more than 35%. The scientists presented the treatment outcomes and the rate of patient survival in the conference.
A team of Indian researchers Dr. Sumana Premkumar of Kamashi Memorial Hospital, Dr. Ramanan, MCCF and Dr. Deenadayalan from Apollo Hospitals, Chennai presented analogous data studied on Indian patients. The data briefed AIET experimentations in Indian patients, and research trials observed increased survival rate among AIET-received patients by more than two years in Stage-IV diagnosed ovarian cancer patient. The AIET increased the survival rate of a patient by more than three years in an ovarian cancer patient, and survival is more than six years in Ph+ ALL patients.
As supporting evidence, Dr. Dedeepiya Devaprasad advocated the clinical significance of AIET combined therapy with monoclonal antibodies based on the clinical trials. In the study, he observed AIET increased survival of an inoperable pancreatic malignancy patient by three years, post-diagnosis.